Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Bandage-Like matrix could speed healing after skin cancer removal

NCT ID NCT06578650

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a synthetic fiber matrix called Restrata, placed directly into surgical wounds after skin cancer removal. Researchers will track how long it takes for the wound bed to granulate (fill in with new tissue) and fully heal. The trial enrolls 34 adults with wounds between 4 and 36 square centimeters.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Synthetic electrospun fiber matrix (Restrata)
What this could lead to
If it works, this could provide a faster, more effective way to heal wounds after skin cancer surgery, reducing recovery time and complications.
What could go wrong
This is a small, early-stage trial with only 34 participants and no comparison group, so results may not apply to everyone. The device may not improve healing over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be enrolled in a University Hospital Setting

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient is at least 18 years old 2. Patient plans to undergo surgical resection of a cutaneous neoplasm 3. Patient is willing and capable of complying with all protocol requirements 4. Patient or legally authorized representative (LAR) is willing to provide written informed consent prior to participation in study 5. Post-resection surgical wound with a surface area of ≥4 cm2 and ≤ 36cm2 Exclusion Criteria: 1. Inability to give informed consent or to complete the procedures required for study completion 2. Patient has been previously enrolled into this study, or is currently participating in another drug or device study that has not reached its primary endpoint 3. Patient is pregnant, breast feeding or planning to become pregnant 4. Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS) 5. Patients receiving any immunotherapy, radiation, or chemotherapy within the past four weeks prior to resection surgery. 6. Patient has a life expectancy less than six months as assessed by the investigator 7. Patient has an additional non-study related wound within 3 cm of the study wound 8. Study wound is located on the hands or feet 9. Patient has been diagnosed with osteomalacia 10. Resection defect from a squamous cell carcinoma arising from a chronic wound 11. Patient has an uncontrolled thyroid disorder 12. Hgb A1c \> 12% within 3 months prior to enrollment in patients with a known history of diabetes 13. Patient has a BMI \> 34.9 14. Patient has used any tobacco product within the past 30 days prior to surgery 15. Patients with chronic kidney disease on peritoneal or hemodialysis, or with an estimated glomerular filtration rate less than 15mL/min 16. Patients with severe liver disease with active cirrhosis defined as a gross ascites upon clinical exam or a Model for End-stage Liver Disease (MELD)-Na score greater than 15 17. Patient not in reasonable metabolic control in the judgement of the investigator 18. Patient has a known history of poor compliance with medical treatment 19. Patient has a history of radiotherapy to wound bed of interest 20. Patient has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis 21. Active infection, undrained abscess, or critical colonization of the wound with bacteria in the judgement of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant cutaneous neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

skin cancer Surgical Wound

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Nevada - Las Vegas

    RECRUITING

    Las Vegas, Nevada, 89102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.